Annual CFF
$438.00 K
-$22.10 M-98.06%
December 31, 2023
Summary
- As of February 8, 2025, VIRX annual cash flow from financing activities is $438.00 thousand, with the most recent change of -$22.10 million (-98.06%) on December 31, 2023.
- During the last 3 years, VIRX annual CFF has fallen by -$44.54 million (-99.03%).
- VIRX annual CFF is now -99.30% below its all-time high of $62.42 million, reached on December 31, 2021.
Performance
VIRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$1.92 M
-$1.96 M-4567.44%
September 30, 2024
Summary
- As of February 8, 2025, VIRX quarterly cash flow from financing activities is -$1.92 million, with the most recent change of -$1.96 million (-4567.44%) on September 30, 2024.
- Over the past year, VIRX quarterly CFF has dropped by -$2.14 million (-981.19%).
- VIRX quarterly CFF is now -103.08% below its all-time high of $62.40 million, reached on March 31, 2021.
Performance
VIRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
-$8.26 M
-$1.92 M-30.31%
September 30, 2024
Summary
- As of February 8, 2025, VIRX TTM cash flow from financing activities is -$8.26 million, with the most recent change of -$1.92 million (-30.31%) on September 30, 2024.
- Over the past year, VIRX TTM CFF has dropped by -$8.70 million (-1985.39%).
- VIRX TTM CFF is now -107.69% below its all-time high of $107.38 million, reached on March 31, 2021.
Performance
VIRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
VIRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -98.1% | -981.2% | -1985.4% |
| 3 y3 years | -99.0% | -981.2% | -1985.4% |
| 5 y5 years | -99.0% | -981.2% | -1985.4% |
VIRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -99.3% | at low | -109.0% | +70.9% | -113.2% | at low |
| 5 y | 5-year | -99.3% | at low | -103.1% | +70.9% | -107.7% | at low |
| alltime | all time | -99.3% | at low | -103.1% | +70.9% | -107.7% | at low |
Viracta Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$1.92 M(-4567.4%) | -$8.26 M(+30.3%) |
| Jun 2024 | - | $43.00 K(-100.7%) | -$6.34 M(+2.6%) |
| Mar 2024 | - | -$6.60 M(-3126.6%) | -$6.18 M(-1510.0%) |
| Dec 2023 | $438.00 K(-98.1%) | $218.00 K(>+9900.0%) | $438.00 K(-98.0%) |
| Sep 2023 | - | $0.00(-100.0%) | $21.63 M(-4.9%) |
| Jun 2023 | - | $204.00 K(+1175.0%) | $22.73 M(+0.8%) |
| Mar 2023 | - | $16.00 K(-99.9%) | $22.55 M(+0.0%) |
| Dec 2022 | $22.54 M | $21.41 M(+1840.8%) | $22.54 M(+2308.3%) |
| Sep 2022 | - | $1.10 M(+4495.8%) | $936.00 K(-1284.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2022 | - | $24.00 K(+200.0%) | -$79.00 K(-325.7%) |
| Mar 2022 | - | $8000.00(-104.0%) | $35.00 K(-99.9%) |
| Dec 2021 | $62.42 M(+38.8%) | -$199.00 K(-326.1%) | $62.42 M(-39.0%) |
| Sep 2021 | - | $88.00 K(-36.2%) | $102.35 M(-4.6%) |
| Jun 2021 | - | $138.00 K(-99.8%) | $107.25 M(-0.1%) |
| Mar 2021 | - | $62.40 M(+57.1%) | $107.38 M(+138.7%) |
| Dec 2020 | $44.98 M | $39.72 M(+695.8%) | $44.98 M(+755.8%) |
| Sep 2020 | - | $4.99 M(+1790.9%) | $5.26 M(+1890.9%) |
| Jun 2020 | - | $264.00 K(>+9900.0%) | $264.00 K(>+9900.0%) |
| Mar 2020 | - | $0.00 | $0.00 |
FAQ
- What is Viracta Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Viracta Therapeutics?
- What is Viracta Therapeutics annual CFF year-on-year change?
- What is Viracta Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Viracta Therapeutics?
- What is Viracta Therapeutics quarterly CFF year-on-year change?
- What is Viracta Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Viracta Therapeutics?
- What is Viracta Therapeutics TTM CFF year-on-year change?
What is Viracta Therapeutics annual cash flow from financing activities?
The current annual CFF of VIRX is $438.00 K
What is the all time high annual CFF for Viracta Therapeutics?
Viracta Therapeutics all-time high annual cash flow from financing activities is $62.42 M
What is Viracta Therapeutics annual CFF year-on-year change?
Over the past year, VIRX annual cash flow from financing activities has changed by -$22.10 M (-98.06%)
What is Viracta Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of VIRX is -$1.92 M
What is the all time high quarterly CFF for Viracta Therapeutics?
Viracta Therapeutics all-time high quarterly cash flow from financing activities is $62.40 M
What is Viracta Therapeutics quarterly CFF year-on-year change?
Over the past year, VIRX quarterly cash flow from financing activities has changed by -$2.14 M (-981.19%)
What is Viracta Therapeutics TTM cash flow from financing activities?
The current TTM CFF of VIRX is -$8.26 M
What is the all time high TTM CFF for Viracta Therapeutics?
Viracta Therapeutics all-time high TTM cash flow from financing activities is $107.38 M
What is Viracta Therapeutics TTM CFF year-on-year change?
Over the past year, VIRX TTM cash flow from financing activities has changed by -$8.70 M (-1985.39%)